采用基因表达数据集分析UBE2C与膀胱癌临床病理特征和预后的相关性

Association between UBE2C expression and clinical pathological characteristics as well as prognosis of bladder cancer

目的分析UBE2C基因表达与膀胱癌患者临床病理特征及预后的相关性。方法采用Oncomine数据库整合分析出肌层浸润性膀胱癌与正常膀胱组织表达差异最显著的基因作为候选目的基因,然后采用GSE13507基因表达数据集来分析该目的基因与膀胱癌临床病理特征和预后的相关性。结果 Oncomine数据库分析得到UBE2C为差异最显著的基因。GSE13507基因表达数据集分析结果显示,UBE2C基因表达水平在男性中高于女性(P=0.005),在肌层浸润性膀胱癌患者中高于非肌层浸润性膀胱癌患者(P=0.001),在T分期(P=0.001)和N分期(P=0.036)更高者高于分期更低者,在肿瘤进展患者中高于无进展患者(P=0.011);但在患者年龄(P=0.264)、远处转移(P=0.711)和肿瘤复发(P=0.481)方面无统计学差异。UBE2C基因诊断膀胱癌的曲线下面积为0.804,生存分析显示UBE2C基因高表达组的预后差于低表达组(HR=1.82,95%CI:1.13～2.94,Logrank P=0.011)。结论 UBE2C基因高表达可能与膀胱癌肌层浸润、高T分期、高N分期和不良预后相关。

Objective To analyze the association between UBE2C gene expression and clinical pathological characteristics as well as prognosis of bladder cancer.Methods The candidate hub gene which was the most differential expression gene between muscle invasive bladder cancer(MIBC)and healthy bladder tissues was identified in Oncomine database using integrated analysis.Then the association between the hub gene expression and clinical pathological characteristics and prognosis of bladder cancer was analyzed using GSE13507 gene expression profile.Results The UBE2C gene was the most differential expression gene identified in Oncomine database.The GSE13507 gene expression profile showed that UBE2C gene expression was higher in male than in female(P=0.005),higher in MIBC patients than in non-MIBC patients(P=0.001),higher in T(P=0.001)and N(P=0.036)stages than in the other stages,and higher in tumor progression patients than in non-progression patients(P=0.011).There were no differences in age(P=0.264),distant metastasis(P=0.711),and tumor recurrence(P=0.481).UBE2C gene diagnosis of bladder cancer showed the area under the curve was 0.804.The survival analysis showed that higher expression of UBE2C indicated poorer prognosis(HR=1.82,95%CI:1.13-2.94,Log-rank P=0.011).Conclusion High expression of UBE2C gene may be associated with muscle invasiveness,high N and T stages,and poor prognosis of bladder cancer.